NCT00781105View on ClinicalTrials.gov

Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B

PHASE4CompletedINTERVENTIONAL
Enrollment

2,200

Participants

Timeline

Start Date

August 1, 2008

Primary Completion Date

September 16, 2010

Study Completion Date

September 16, 2010

Conditions
Chronic Hepatitis B
Interventions
DRUG

Telbivudine

600 mg/day, oral tablets, once daily, 52 weeks

Trial Locations (1)

Unknown

Novartis Investigative Site, Beijing

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY